478510-91-7

Usage

Uses

Used in Pharmaceutical Applications:
[5'-13C]2'-DEOXYURIDINE is used as a therapeutic agent for the treatment of various medical conditions, including allergies, cancer, infections, and autoimmune diseases. The incorporation of the 13C isotope enables the tracking and analysis of the compound's behavior within biological systems, providing valuable insights into its mechanism of action and potential therapeutic effects.
Used in Research and Development:
In the field of research, [5'-13C]2'-DEOXYURIDINE serves as an essential tool for studying the metabolic pathways and interactions of uridine and its derivatives. The isotope labeling allows for the differentiation between the labeled compound and endogenous molecules, facilitating the investigation of its biological processes and potential applications in drug development.
Used in Diagnostic Applications:
The isotope-labeled nature of [5'-13C]2'-DEOXYURIDINE also makes it a valuable asset in diagnostic applications. It can be utilized in the development of diagnostic tests and imaging techniques that rely on the detection of specific isotopes, providing a means to monitor disease progression and evaluate the effectiveness of treatments.
Used in Drug Delivery Systems:
Similar to gallotannin, [5'-13C]2'-DEOXYURIDINE can be incorporated into novel drug delivery systems to enhance its applications and efficacy against specific diseases. The use of organic and metallic nanoparticles as carriers for the isotope-labeled compound can improve its delivery, bioavailability, and therapeutic outcomes, particularly in the treatment of cancer and other complex diseases.

Upstream product

• 66-22-8 uracil 

Relevant academic research and scientific papers

One-pot two-step enzymatic coupling of pyrimidine bases to 2-deoxy-D-ribose-5-phosphate. A new strategy in the synthesis of stable isotope labeled deoxynucleosides

The enzymatic synthesis of thymidine from 2-deoxy-D-ribose-5-phosphate is achieved, in a one-pot two-step reaction using phosphoribomutase (PRM) and commercially available thymidine phosphorylase (TP). In the first step the sugar-5-phosphate is enzymatically rearranged to α-2-deoxy-D-ribose-1-phosphate. Highly active PRM is easily obtained from genetically modified overproducing E. coli cells (12000 units/84 mg protein) and is used without further purification. In the second step thymine is coupled to the sugar-1-phosphate. The thermodynamically unfavorable equilibrium is shifted to the product by addition of MnCl2 to precipitate inorganic phosphate. In this way the overall yield of the β-anomeric pure nucleoside increases from 14 to 60%. In contrast to uracil, cytosine is not accepted by TP as a substrate. Therefore, 2′-deoxy-cytidine is obtained by functional group transformations of the enzymatically prepared 2′-deoxy-uridine. The method has been demonstrated by the synthesis of [2′,5′-13C2]- and [1′,2′,5′-13C3]thymidine as well as [1′,2′,5′-13C3]2′-deoxyuridine and [3′,4′-13C2]2′-deoxycytidine. In addition the nucleoside bases thymine and uracil are tetralabeled at the (1,3-15N2,2,4-13C2)-atomic positions. All compounds are prepared without any scrambling or dilution of the labeled material and are thus obtained with a very high isotope enrichment (96-99%). In combination with the methods that have been developed earlier it is concluded that each of the 13C- and 15N-positions and combination of positions of the pyrimidine deoxynucleosides can be efficiently labeled starting from commercially available and highly 13C- or 15N-enriched formaldehyde, acetaldehyde, acetic acid, potassium cyanide, methylamine hydrochloride, and ammonia.